Predicting who benefits from checkpoint blockade: the tumour immune microenvironment, quantitative mismatch-repair and microsatellite measures, and the co-medications that blunt a response before it starts.
In a correlative biomarker analysis of the HCRN GU16-260 trial, non-exhausted CD8+ T cells were linked to higher response rates and longer progression-free survival in treatment-naive metastatic clear-cell RCC treated with first-line nivolumab.
A post-hoc analysis of the phase III PACIFIC trial (660 of 713 originally randomized patients; 449 durvalumab, 211 placebo) examined whether baseline exposure to proton pump inhibitors (PPIs) or antibiotics was associated with worse outcomes after consolidation durvalumab for unresectable stage III NSCLC, at a median follow-up of 62.4 months.
Retrospective, single-center biomarker cohort study of 39 patients with dMMR metastatic colorectal cancer treated with anti-PD-1 monotherapy at Mayo Clinic, using integrated exome, transcriptome, and immune-repertoire profiling to test whether quantitative MSI burden — not just binary MSI-high status — predicts benefit from checkpoint blockade